Effectiveness and safety of Maxing Shigan Decoction for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background and objective

Community-acquired pneumonia (CAP) is an acute lung infection disease with high morbidity and mortality. The treatment of CAP has become more and more challenging due to the gradual increase of antibiotic resistance and adverse events. Relevant evidence indicates that Maxing Shigan Decoction (MXSG) may play a unique therapeutic advantage. Our aim is to evaluate the overall effectiveness and safety of MXSG for CAP.

Methods

Eight databases (PubMed, Embase, the Cochrane Library, CNKI, Wanfang, VIP, Yiigle, and Sinomed) were searched from their inception to January 20, 2025. Randomized controlled trials evaluating the effectiveness and safety of MXSG alone or in combination with conventional western medicine (WM) for CAP were included. We conducted meta-

SUBMITTER: Ling Y 

PROVIDER: S-EPMC12425732 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature